In addition, elevated expression of i-genes (BTN3A2, CD2, and TRBC1) was significantly correlated with favorable clinical outcome in HR−/HER2+ breast cancer, but not in other subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.